- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05226390
Safety, Reactogenicity and Immunogenicity of a Novel MVA-SARS-2-ST Vaccine Candidate
Safety, Reactogenicity and Immunogenicity of a Novel MVA-SARS-2-ST Vaccine Candidate Administered as Inhalation Boost in SARS-CoV-2 Immunized Adults - Phase I Study
This will be a phase I, single-center trial, including a total of 30 participants in two cohorts.
Cohort 1 (n=6): Healthy male or female adults aged 18 - ≤ 60 previously primary immunized with two vaccinations with any regimen using any EU marketed SARS-CoV-2 vaccine (mRNA-, vector-, protein-based, attenuated SARS-CoV-2 virus) or with a single application of COVID-19 Vaccine Janssen.
Cohort 2 (n=24): Healthy male or female adults aged 18 - ≤ 60 primary immunized with two vaccinations with any regimen using any EU marketed SARS-CoV-2 vaccine (mRNA-, vector-, protein-based, attenuated SARS-CoV-2 virus) or with a single application of COVID-19 Vaccine Janssen and subsequently booster immunized with any EU marketed mRNA vaccine
Both cohorts will be assigned to inhaled vaccination with MVA-SARS-2-ST
Study Overview
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Contact
- Name: Breuer
- Phone Number: +49 176 1 532-7242
- Email: mva-sars-2-s.zks@mh-hannover.de
Study Contact Backup
- Name: Papkalla
- Phone Number: +49 176 1 532-7229
- Email: mva-sars-2-s.zks@mh-hannover.de
Study Locations
-
-
-
Hannover, Germany, 30625
- Hannover Medical School ZKS - Early Clinical Trial Unit at CRC Hannover
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
The subject must not be enrolled before all inclusion criteria (including test results) are confirmed. Subjects meeting all of the criteria listed below will be included in the study.
- Signed written informed consent from subject prior to any study-related procedure and willingness to comply with treatment and follow-up procedures
Healthy men or women, aged ≥ 18 ≤ 60 at day of inclusion having received either
- primary immunization (cohort 1) with any regimen using any EU marketed SARS- CoV-2 vaccine or
- subsequently booster immunization (cohort 2) with any EU marketed mRNA vaccine
at least 3 months prior to enrollment
- Adults with SARS-CoV-2 specific IgG concentration between 10 RU/ml and 1200 RU/ml determined by Anti-SARS-CoV-2-QuantiVac-ELISA (IgG)
Males or non-pregnant, non-lactating females of child-bearing potential with negative pregnancy test at screening who agree to comply with the applicable contraceptive requirements of the protocol (Section 3.4) from at least 14 days prior to vaccination and during the entire duration of the study.
or
Females without child-bearing potential defined as follows:
- at least 6 weeks after surgical sterilization by bilateral tubal ligation or bilateral oophorectomy or
- hysterectomy or uterine agenesis or
- ≥ 50 years and in postmenopausal state > 1 year or
- < 50 years and in postmenopausal state > 1 year with serum FSH > 40 IU/l and serum estrogen < 30 ng/l or a negative estrogen test, both at screening
- Normal pulmonary function: FEV1 predicted ≥ 80% and FEV1/FVC > 70%
- Body mass index 18.5 - 30.0 kg/m2 and weight > 50 kg at screening
- Subject is capable of understanding the investigational nature, potential risks and benefits of the clinical trial
Exclusion Criteria:
Subjects are excluded from the study if any of the following criteria are met at screening or on dosing day.
- Previous MVA or rMVA vaccination
- Known allergy to the components of the SARS-CoV-2 vaccine product as chicken proteins or history of life-threatening reactions to vaccine containing the same substances
- Known history of anaphylaxis to vaccination or any allergy likely to be exacerbated by any component of the trial vaccine
- Any laboratory value outside the reference range that the investigator considers to be of clinical relevance; safety laboratory screening evaluation can be repeated a maximum of two times
- Any finding in the medical history and physical examination deviating from normal and assessed as clinically relevant by the investigator
- Evidence in the subject's medical history or in the medical examination that might influence the absorption, distribution, metabolism or excretion of the investigational medicinal product
- Current smoking/ vaping or smoking /vaping in the previous year.
- Clinically relevant findings in ECG
- Any confirmed or suspected immunosuppressive or immunodeficient condition, cytotoxic therapy in the previous 5 years, and/or diabetes
- Asthma, chronic obstructive pulmonary disease or other lung disease
- Respiratory tract infection in the 4 weeks prior to study treatment
- Any chronic or active neurologic disorder, including seizures, and epilepsy, excluding a single febrile seizure as a child
- Known intolerance to medication used during bronchoscopy, i.e. midazolam and lidocaine.
- Treatment with ß-adrenoceptor antagonists
- Alcohol abuse (consumption of more than 20 g per day for females and 30 g per day for males)
- Drug abuse or positive drug screening
- Any positive result for HIV1/2, HCV antibody or HBs antigen testing
- Moderate or severe illness and/or fever >38 °C within 1 week prior to vaccination
- History of blood donation within 60 days of enrollment or plans to donate within the treatment phase
- Participation in a clinical trial or use of an investigational product within 30 days or five times the half-life of the investigational product -whichever is longer- prior to receiving the first dose within this study
- Investigator or employee of the study site or Sponsor with direct involvement in the proposed study, or identified as an immediate family member (i.e., parent, natural or adopted child) of the investigator or employee with direct involvement in the proposed study
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: 1 x 107 IU/dose MVA-SARS-2-ST
All Participants will receive a single booster dose of 1 x 107 IU MVA-SARS-2-ST in 0.5 mL as inhalation (total inhaled volume 0.5 mL)
|
In this trial MVA-SARS-2-ST will be used.
Each vial contains 1 x 107 IU/dose MVA-SARS-2-ST in 0.5 mL as active ingredient.
The solution will be used for nebulization and direct administration to the respiratory tract.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The nature, frequency and severity of adverse events associated with MVA-SARS-2-ST
Time Frame: day 0
|
Occurrence of solicited local reactogenicity signs and symptoms
|
day 0
|
The nature, frequency and severity of adverse events associated with MVA-SARS-2-ST
Time Frame: day 1
|
Occurrence of solicited local reactogenicity signs and symptoms
|
day 1
|
The nature, frequency and severity of adverse events associated with MVA-SARS-2-ST
Time Frame: day 2
|
Occurrence of solicited local reactogenicity signs and symptoms
|
day 2
|
The nature, frequency and severity of adverse events associated with MVA-SARS-2-ST
Time Frame: day 3
|
Occurrence of solicited local reactogenicity signs and symptoms
|
day 3
|
The nature, frequency and severity of adverse events associated with MVA-SARS-2-ST
Time Frame: day 4
|
Occurrence of solicited local reactogenicity signs and symptoms
|
day 4
|
The nature, frequency and severity of adverse events associated with MVA-SARS-2-ST
Time Frame: day 5
|
Occurrence of solicited local reactogenicity signs and symptoms
|
day 5
|
The nature, frequency and severity of adverse events associated with MVA-SARS-2-ST
Time Frame: day 6
|
Occurrence of solicited local reactogenicity signs and symptoms
|
day 6
|
The nature, frequency and severity of adverse events associated with MVA-SARS-2-ST
Time Frame: day 7
|
Occurrence of solicited local reactogenicity signs and symptoms
|
day 7
|
Change from baseline of pulmonary function associated with MVA-SARS-2-ST
Time Frame: day 0 (2h), day 1, 3, 7, 14, 28, 56, 140
|
Change from baseline of pulmonary function measured by spirometry as forced vital capacity (FVC) (%)
|
day 0 (2h), day 1, 3, 7, 14, 28, 56, 140
|
Change from baseline of pulmonary function associated with MVA-SARS-2-ST
Time Frame: day 0 (2h), day 1, 3, 7, 14, 28, 56, 140
|
Change from baseline of pulmonary function measured by spirometry as forced expiratory volume in 1 second (FEV1) (%)
|
day 0 (2h), day 1, 3, 7, 14, 28, 56, 140
|
Change from baseline of pulmonary function associated with MVA-SARS-2-ST
Time Frame: day 0 (2h), day 1, 3, 7, 14, 28, 56, 140
|
Change from baseline of pulmonary function measured by spirometry as FEV1/FVC (%)
|
day 0 (2h), day 1, 3, 7, 14, 28, 56, 140
|
Change from baseline of pulmonary function associated with MVA-SARS-2-ST
Time Frame: day 0 and twice daily on days 1, 2, 3, 4, 5, 6, 7
|
Change from baseline of pulmonary function measured by peak flow as peak expiratory flow (PEF) frequently
|
day 0 and twice daily on days 1, 2, 3, 4, 5, 6, 7
|
Occurrence of solicited systemic reactogenicity signs and symptoms associated with MVA-SARS-2-ST
Time Frame: day 0
|
Occurrence of solicited systemic reactogenicity signs and symptoms vaccination
|
day 0
|
Occurrence of solicited systemic reactogenicity signs and symptoms associated with MVA-SARS-2-ST
Time Frame: day 1
|
Occurrence of solicited systemic reactogenicity signs and symptoms vaccination
|
day 1
|
Occurrence of solicited systemic reactogenicity signs and symptoms associated with MVA-SARS-2-ST
Time Frame: day 2
|
Occurrence of solicited systemic reactogenicity signs and symptoms vaccination
|
day 2
|
Occurrence of solicited systemic reactogenicity signs and symptoms associated with MVA-SARS-2-ST
Time Frame: day 3
|
Occurrence of solicited systemic reactogenicity signs and symptoms vaccination
|
day 3
|
Occurrence of solicited systemic reactogenicity signs and symptoms associated with MVA-SARS-2-ST
Time Frame: day 4
|
Occurrence of solicited systemic reactogenicity signs and symptoms vaccination
|
day 4
|
Occurrence of solicited systemic reactogenicity signs and symptoms associated with MVA-SARS-2-ST
Time Frame: day 5
|
Occurrence of solicited systemic reactogenicity signs and symptoms vaccination
|
day 5
|
Occurrence of solicited systemic reactogenicity signs and symptoms associated with MVA-SARS-2-ST
Time Frame: day 6
|
Occurrence of solicited systemic reactogenicity signs and symptoms vaccination
|
day 6
|
Occurrence of solicited systemic reactogenicity signs and symptoms associated with MVA-SARS-2-ST
Time Frame: day 7
|
Occurrence of solicited systemic reactogenicity signs and symptoms vaccination
|
day 7
|
Occurrence of unsolicited adverse events (AE) associated with MVA-SARS-2-ST
Time Frame: from day 0 to day 28 after vaccination
|
Occurrence of unsolicited adverse events (AE)
|
from day 0 to day 28 after vaccination
|
Change of safety laboratory measures associated with MVA-SARS-2-S
Time Frame: day 1, 3, 7, 14, 28, 56, 140
|
Change from baseline of safety laboratory measures
|
day 1, 3, 7, 14, 28, 56, 140
|
Occurrence of serious adverse events (SAE) associated with MVA-SARS-2-ST
Time Frame: through study completion, an average of 5 month
|
Occurrence of serious adverse events (SAE)
|
through study completion, an average of 5 month
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
To evaluate immunogenicity of the candidate MVA-SARS-2-ST
Time Frame: day 7, 14, 28, 56 and 140
|
Change from baseline of levels of binding antibodies against SARS-CoV-2 spike S1 protein measured by ELISA in blood
|
day 7, 14, 28, 56 and 140
|
To evaluate immunogenicity of the candidate MVA-SARS-2-ST
Time Frame: day 14
|
Change from baseline of levels of binding antibodies against SARS-CoV-2 spike S1 protein measured by ELISA in (bronchial alveolar lavage) BAL on day 14
|
day 14
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Jens Hohlfeld, Prof., Hannover Medical School, Department of Respiratory Medicine and Fraunhofer ITEM, Division of Clinical Airway Research
- Study Chair: Reinhold Förster, Prof., Hannover Medical School Institute of Immunology
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Other Study ID Numbers
- MVA-S2-S-R01
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on COVID-19 Vaccines
-
Hospices Civils de LyonCompletedHemodialysis Complication | COVID-19 VaccinesFrance
-
Centers for Disease Control and Prevention, ChinaRecruitingPneumococcal Vaccines | Safety | Influenza Vaccines | COVID-19 Vaccines | Immunogenicity, VaccineChina
-
Dr. Soetomo General HospitalIndonesia-MoH; Universitas Airlangga; Biotis Pharmaceuticals, IndonesiaRecruitingCOVID-19 Pandemic | COVID-19 Vaccines | COVID-19 Virus DiseaseIndonesia
-
Dr. Soetomo General HospitalIndonesia-MoH; Universitas Airlangga; PT Biotis Pharmaceuticals, IndonesiaRecruitingCOVID-19 Pandemic | COVID-19 VaccinesIndonesia
-
University of MichiganNational Institute on Minority Health and Health Disparities (NIMHD); National...Recruiting
-
Dr. Soetomo General HospitalIndonesia-MoH; Universitas Airlangga; Biotis Pharmaceuticals, IndonesiaRecruitingCOVID-19 Pandemic | COVID-19 VaccinesIndonesia
-
Dr. Soetomo General HospitalIndonesia-MoH; Universitas Airlangga; Biotis Pharmaceuticals, IndonesiaRecruitingCOVID-19 Pandemic | COVID-19 VaccinesIndonesia
-
Dr. Soetomo General HospitalIndonesia-MoH; Universitas Airlangga; PT Biotis Pharmaceuticals, IndonesiaActive, not recruitingCOVID-19 Pandemic | COVID-19 VaccinesIndonesia
-
University Hospital, Strasbourg, FranceRecruitingCOVID-19 VaccinesFrance
-
Institute of Agrochemistry and Food Technology,...Universitat Jaume I; Hospital Universitario La Fe; University of Barcelona; Hospital... and other collaboratorsCompleted
Clinical Trials on MVA-SARS-2-ST
-
Universitätsklinikum Hamburg-EppendorfLudwig-Maximilians - University of Munich; Philipps University Marburg Medical... and other collaboratorsCompleted
-
Universitätsklinikum Hamburg-EppendorfLudwig-Maximilians - University of Munich; University Hospital Tuebingen; Philipps... and other collaboratorsWithdrawn
-
Universitätsklinikum Hamburg-EppendorfLudwig-Maximilians - University of Munich; Philipps University Marburg Medical... and other collaboratorsCompleted
-
GeoVax, Inc.National Cancer Institute (NCI); City of Hope Medical CenterActive, not recruitingCOVID-19 InfectionUnited States
-
GeoVax, Inc.National Cancer Institute (NCI)RecruitingLymphoma | Leukemia | Plasma Cell Myeloma | Hematopoietic and Lymphoid System Neoplasm | COVID-19 InfectionUnited States
-
City of Hope Medical CenterNational Cancer Institute (NCI)RecruitingChronic Lymphocytic Leukemia | COVID-19 InfectionUnited States
-
Everly HealthCompletedSARS-CoV-2 Acute Respiratory DiseaseUnited States
-
Meshalkin Research Institute of Pathology of CirculationUnknown
-
Universidade Nova de LisboaRecruitingCoronavirus Infection | Pregnancy Complications | Breastfeeding | Neonatal Infection | Vertical Transmission of Infectious DiseasePortugal
-
Stemirna TherapeuticsNot yet recruiting